The ErbB kinase domain: Structural perspectives into kinase activation and inhibition

Experimental Cell Research

Volumn 315, Issue 4, 2009, Pages 649-658

  Bose, Ron ^a   Zhang, Xuewu ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Activation loop; Epidermal growth factor receptor; Growth factor receptor; Lung cancer; MIG6; Receptor dimerization; Receptor tyrosine kinase; Signal transduction; Structural biology; Tyrosine kinase inhibitor

Indexed keywords

ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MEMBRANE PROTEIN;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; ENZYME ACTIVATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; PROTEIN TERTIARY STRUCTURE; REVIEW;

ANIMALS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 62649103876     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.07.031     Document Type: Review

References (80)

1. A.B. Schreiber, T.A. Libermann, I. Lax, Y. Yarden, J. Schlessinger, Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies, J. Biol. Chem. 258 (1983) 846-853.
2. J. Schlessinger, Ligand-induced, receptor-mediated dimerization and activation of EGF receptor, Cell 110 (2002) 669-672.
3. H. Ushiro, S. Cohen, Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes, J. Biol. Chem. 255 (1980) 8363-8365.
4. Y. Yarden, J. Schlessinger, Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation, Biochemistry 26 (1987) 1434-1442.
5. Y. Yarden, J. Schlessinger, Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor, Biochemistry 26 (1987) 1443-1451.
6. H.S. Cho, D.J. Leahy, Structure of the extracellular region of HER3 reveals an interdomain tether, Science 297 (2002) 1330-1333.
7. T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, G.O. Lovrecz, H.J. Zhu, F. Walker, M.J. Frenkel, P.A. Hoyne, R.N. Jorissen, E.C. Nice, A.W. Burgess, C.W. Ward, Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha, Cell 110 (2002) 763-773.
8. H. Ogiso, R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, J.H. Kim, K. Saito, A. Sakamoto, M. Inoue, M. Shirouzu, S. Yokoyama, Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains, Cell 110 (2002) 775-787.
9. H.S. Cho, K. Mason, K.X. Ramyar, A.M. Stanley, S.B. Gabelli, D.W. Denney Jr., D.J. Leahy, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature 421 (2003) 756-760.
10. K.M. Ferguson, M.B. Berger, J.M. Mendrola, H.S. Cho, D.J. Leahy, M.A. Lemmon, EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization, Mol. Cell 11 (2003) 507-517.
11. T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, G.O. Lovrecz, M. Kofler, R.N. Jorissen, E.C. Nice, A.W. Burgess, C.W. Ward, The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors, Mol. Cell 11 (2003) 495-505.
12. S.R. Hubbard, Structural analysis of receptor tyrosine kinases, Prog. Biophys. Mol. Biol. 71 (1999) 343-358.
13. M. Huse, J. Kuriyan, The conformational plasticity of protein kinases, Cell 109 (2002) 275-282.
14. N. Gotoh, A. Tojo, M. Hino, Y. Yazaki, M. Shibuya, A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor, Biochem. Biophys. Res. Commun. 186 (1992) 768-774.
15. J. Stamos, M.X. Sliwkowski, C. Eigenbrot, Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor, J. Biol. Chem. 277 (2002) 46265-46272.
16. F. Canals, Signal transmission by epidermal growth factor receptor: coincidence of activation and dimerization Biochemistry 31 (1992) 4493-4501.
17. I. Posner, M. Engel, A. Levitzki, Kinetic model of the epidermal growth factor (EGF) receptor tyrosine kinase and a possible mechanism of its activation by EGF, J. Biol. Chem. 267 (1992) 20638-20647.
18. C. Erneux, S. Cohen, D.L. Garbers, The kinetics of tyrosine phosphorylation by the purified epidermal growth factor receptor kinase of A-431 cells, J. Biol. Chem. 258 (1983) 4137-4142.
19. Y. Yarden, J. Schlessinger, The EGF receptor kinase: evidence for allosteric activation and intramolecular self-phosphorylation, Ciba Found Symp. 116 (1985) 23-45.
20. M. Mohammadi, A. Honegger, A. Sorokin, A. Ullrich, J. Schlessinger, D.R. Hurwitz, Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase, Biochemistry 32 (1993) 8742-8748.
21. P.B. Wedegaertner, G.N. Gill, Activation of the purified protein tyrosine kinase domain of the epidermal growth factor receptor, J. Biol. Chem. 264 (1989) 11346-11353.
22. E.R.Wood, A.T. Truesdale, O.B. McDonald, D. Yuan, A. Hassell, S.H. Dickerson, B. Ellis, C. Pennisi, E. Horne, K. Lackey, K.J. Alligood, D.W. Rusnak, T.M. Gilmer, L. Shewchuk, A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells, Cancer Res. 64 (2004) 6652-6659.
23. H.L. De Bondt, J. Rosenblatt, J. Jancarik, H.D. Jones, D.O. Morgan, S.H. Kim, Crystal structure of cyclin-dependent kinase 2, Nature 363 (1993) 595-602.
24. W. Xu, A. Doshi, M. Lei, M.J. Eck, S.C. Harrison, Crystal structures of c-Src reveal features of its autoinhibitory mechanism, Mol. Cell 3 (1999) 629-638.
25. T. Schindler, F. Sicheri, A. Pico, A. Gazit, A. Levitzki, J. Kuriyan, Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor, Mol. Cell 3 (1999) 639-648.
26. X. Zhang, J. Gureasko, K. Shen, P.A. Cole, J. Kuriyan, An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor, Cell 125 (2006) 1137-1149.
27. X. Zhang, K.A. Pickin, R. Bose, N. Jura, P.A. Cole, J. Kuriyan, Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface, Nature 450 (2007) 741-744.
28. C. Qiu, M.K. Tarrant, S.H. Choi, A. Sathyamurthy, R. Bose, S. Banjade, A. Pal, W.G. Bornmann, M.A. Lemmon, P.A. Cole, D.J. Leahy, Mechanism of activation and inhibition of the HER4/ErbB4 kinase, Structure 16 (2008) 460-467.
29. E.R. Wood, L.M. Shewchuk, B. Ellis, P. Brignola, R.L. Brashear, T.R. Caferro, S.H. Dickerson, H.D. Dickson, K.H. Donaldson, M. Gaul, R.J. Griffin, A.M. Hassell, B. Keith, R. Mullin, K.G. Petrov, M.J. Reno, D.W. Rusnak, S.M. Tadepalli, J.C. Ulrich, C.D. Wagner, D.E. Vanderwall, A.G. Waterson, J.D. Williams, W.L. White, D.E. Uehling, 6-Ethynylthieno[3,2-d]-and 6-ethynylthieno[2,3-d] pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 2773-2778.
30. N.M. Levinson, O. Kuchment, K. Shen, M.A. Young, M. Koldobskiy, M. Karplus, P.A. Cole, J. Kuriyan, A Src-like inactive conformation in the abl tyrosine kinase domain, PLoS Biol. 4 (2006) e144.
31. S. Deindl, T.A. Kadlecek, T. Brdicka, X. Cao, A. Weiss, J. Kuriyan, Structural basis for the inhibition of tyrosine kinase activity of ZAP-70, Cell 129 (2007) 735-746.
32. X. Min, B.H. Lee, M.H. Cobb, E.J. Goldsmith, Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension, Structure 12 (2004) 1303-1311.
33. H. Shigematsu, A.F. Gazdar, Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers, Int. J. Cancer 118 (2006) 257-262.
34. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, M. Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science 304 (2004) 1497-1500.
35. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, D.A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med. 350 (2004) 2129-2139.
36. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, H. Varmus, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 13306-13311.
37. C.H. Yun, T.J. Boggon, Y. Li, M.S. Woo, H. Greulich, M. Meyerson, M.J. Eck, Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity, Cancer Cell. 11 (2007) 217-227.
38. K.D. Carey, A.J. Garton, M.S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J.D. Haley, N. Gibson, M.X. Sliwkowski, Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, Cancer Res. 66 (2006) 8163-8171.
39. S.H. Choi, J.M. Mendrola, M.A. Lemmon, EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer, Oncogene 26 (2007) 1567-1576.
40. M. Landau, N. Ben-Tal, Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors, Biochim. Biophys. Acta 1785 (2008) 12-31.
41. M. Landau, S.J. Fleishman, N. Ben-Tal, A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains, Structure 12 (2004) 2265-2275.
42. L.C. Groenen, F. Walker, A.W. Burgess, H.R. Treutlein, A model for the activation of the epidermal growth factor receptor kinase involvement of an asymmetric dimer? Biochemistry 36 (1997) 3826-3836.
43. K.W. Thiel, G. Carpenter, Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation, Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 19238-19243.
44. Y. Yarden, M.X. Sliwkowski, Untangling the ErbB signalling network, Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137.
45. S.R. Hubbard, Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog, EMBO J. 16 (1997) 5572-5581.
46. O. Segatto, F. Lonardo, J.H. Pierce, D.P. Bottaro, P.P. Di Fiore, The role of autophosphorylation in modulation of erbB-2 transforming function, New Biol. 2 (1990) 187-195.
47. H.T. Zhang, D.M. O'Rourke, H. Zhao, R. Murali, Y. Mikami, J.G. Davis, M.I. Greene, X. Qian, Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential, Oncogene 16 (1998) 2835-2842.
48. J.S. Biscardi, M.C. Maa, D.A. Tice, M.E. Cox, T.H. Leu, S.J. Parsons, c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function, J. Biol. Chem. 274 (1999) 8335-8343.
49. R. Bose, H. Molina, A.S. Patterson, J.K. Bitok, B. Periaswamy, J.S. Bader, A. Pandey, P.A. Cole, Phosphoproteomic analysis of Her2/ neu signaling and inhibition, Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 9773-9778.
50. M. Mukherji, L.M. Brill, S.B. Ficarro, G.M. Hampton, P.G. Schultz, A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways, Biochemistry 45 (2006) 15529-15540.
51. A.Wolf-Yadlin, N. Kumar, Y. Zhang, S. Hautaniemi, M. Zaman, H.D. Kim, V. Grantcharova, D.A. Lauffenburger, F.M. White, Effects of HER2 overexpression on cell signaling networks governing proliferation and migration, Mol. Syst. Biol. 2 (2006) 54.
52. F. Chiara, S. Bishayee, C.-H. Heldin, J.-B. Demoulin, Autoinhibition of the platelet-derived growth factor {beta}-receptor tyrosine kinase by its C-terminal tail, J. Biol. Chem. 279 (2004) 19732-19738.
53. L.M. Shewchuk, A.M. Hassell, B. Ellis, W.D. Holmes, R. Davis, E.L. Horne, S.H. Kadwell, D.D. McKee, J.T. Moore, Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail, Structure Fold Des. 8 (2000) 1105-1113.
54. S.R. Hubbard, Juxtamembrane autoinhibition in receptor tyrosine kinases, Nat. Rev. Mol. Cell Biol. 5 (2004) 464-471.
55. S. Aifa, J. Aydin, G. Nordvall, I. Lundstrom, S.P. Svensson, O. Hermanson, A basic peptide within the juxtamembrane region is required for EGF receptor dimerization, Exp. Cell Res. 302 (2005) 108-114.
56. C.M. Chang, H.K. Shu, L. Ravi, R.J. Pelley, H. Shu, H.J. Kung, A minor tyrosine phosphorylation site located within the CAIN domain plays a critical role in regulating tissue-specific transformation by erbB kinase, J. Virol. 69 (1995) 1172-1180.
57. L. Frederick, X.-Y. Wang, G. Eley, C.D. James, Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas, Cancer Res. 60 (2000) 1383-1387.
58. M. Wick, C. Burger, M. Funk, R. Muller, Identification of a novel mitogen-inducible gene (mig-6): regulation during G1 progression and differentiation, Exp. Cell Res. 219 (1995) 527-535.
59. L. Fiorentino, C. Pertica, M. Fiorini, C. Talora, M. Crescenzi, L. Castellani, S. Alema, P. Benedetti, O. Segatto, Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain, Mol. Cell Biol. 20 (2000) 7735-7750.
60. P.O. Hackel, M. Gishizky, A. Ullrich, Mig-6 is a negative regulator of the epidermal growth factor receptor signal, Biol. Chem. 382 (2001) 1649-1662.
61. S.Anastasi, M.F. Baietti, Y. Frosi, S. Alema,O.Segatto,The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity, Oncogene 26 (2007) 7833-7846.
62. S. Anastasi, L. Fiorentino, M. Fiorini, R. Fraioli, G. Sala, L. Castellani, S. Alema, M. Alimandi, O. Segatto, Feedback inhibition by RALT controls signal output by the ErbB network, Oncogene 22 (2003) 4221-4234.
63. D. Xu, A. Makkinje, J.M. Kyriakis, Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function, J. Biol. Chem. 280 (2005) 2924-2933.
64. S. Anastasi, G. Sala, C. Huiping, E. Caprini, G. Russo, S. Iacovelli, F. Lucini, S. Ingvarsson, O. Segatto, Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin, Oncogene 24 (2005) 4540-4548.
65. I. Ferby, M. Reschke, O. Kudlacek, P. Knyazev, G. Pante, K. Amann, W. Sommergruber, N. Kraut, A. Ullrich, R. Fassler, R. Klein, Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation, Nat. Med. 12 (2006) 568-573.
66. Y.W. Zhang, B. Staal, Y. Su, P. Swiatek, P. Zhao, B. Cao, J. Resau, R. Sigler, R. Bronson, G.F. Vande Woude, Evidence that MIG-6 is a tumor-suppressor gene, Oncogene 26 (2007) 269-276.
67. C. Ballaro, S. Ceccarelli, C. Tiveron, L. Tatangelo, A.M. Salvatore, O. Segatto, S. Alema, Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved-like phenotype, EMBO Rep. 6 (2005) 755-761.
68. F. Shen, Q. Lin, Y. Gu, C. Childress, W. Yang, Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation, Mol. Biol. Cell 18 (2007) 732-742.
69. M. Lei, M.A. Robinson, S.C. Harrison, The active conformation of the PAK1 kinase domain, Structure 13 (2005) 769-778.
70. R.S. Depetris, J. Hu, I. Gimpelevich, L.J. Holt, R.J. Daly, S.R. Hubbard, Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14, Mol. Cell 20 (2005) 325-333.
71. J. Baselga, Targeting tyrosine kinases in cancer: the second wave, Science 312 (2006) 1175-1178.
72. C.H. Yun, K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, K.K. Wong, M. Meyerson, M.J. Eck, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 2070-2075.
73. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, H. Varmus, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS. Med. 2 (2005) e73.
74. E.L. Kwak, R. Sordella, D.W. Bell, N. Godin-Heymann, R.A. Okimoto, B.W. Brannigan, P.L. Harris, D.R. Driscoll, P. Fidias, T.J. Lynch, S.K. Rabindran, J.P. McGinnis, A. Wissner, S.V. Sharma, K.J. Isselbacher, J. Settleman, D.A. Haber, Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib, Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 7665-7670.
75. D.W. Fry, Mechanism of action of erbB tyrosine kinase inhibitors, Exp. Cell Res. 284 (2003) 131-139.
76. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, J. Kuriyan, Structural mechanism for STI-571 inhibition of abelson tyrosine kinase, Science 289 (2000) 1938-1942.
77. H. Greulich, T.H. Chen, W. Feng, P.A. Janne, J.V. Alvarez, M. Zappaterra, S.E. Bulmer, D.A. Frank, W.C. Hahn, W.R. Sellers, M. Meyerson, Oncogenic transformation by inhibitor-sensitive andresistant EGFR mutants, PLoS Med. 2 (2005) e313.
78. H. Shigematsu, T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki, H. Lee, Wistuba, K.M. Fong, S. Toyooka, N. Shimizu, T. Fujisawa, J.D. Minna, A.F. Gazdar, Somatic mutations of the HER2 kinase domain in lung adenocarcinomas, Cancer Res. 65 (2005) 1642-1646.
79. S.E. Wang, A. Narasanna, M. Perez-Torres, B. Xiang, F.Y. Wu, S. Yang, G. Carpenter, A.F. Gazdar, S.K. Muthuswamy, C.L. Arteaga, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors, Cancer Cell 10 (2006) 25-38.
80. Y. Minami, T. Shimamura, K. Shah, T. LaFramboise, K.A. Glatt, E. Liniker, C.L. Borgman, H.J. Haringsma, W. Feng, B.A. Weir, A.M. Lowell, J.C. Lee, J. Wolf, G.I. Shapiro, K.K. Wong, M. Meyerson, R.K. Thomas, The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272, Oncogene 26 (2007) 5023-5027.